Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta

BACKGROUND: Amyloid-β (Aβ) immunotherapy is a promising therapeutic strategy in the fight against Alzheimer’s disease (AD). A number of monoclonal antibodies have entered clinical trials for AD. Some of them have failed due to the lack of efficacy or side-effects, two antibodies are currently in pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Rofo, Fadi, Buijs, Jos, Falk, Ronny, Honek, Ken, Lannfelt, Lars, Lilja, Anna M., Metzendorf, Nicole G., Gustavsson, Tobias, Sehlin, Dag, Söderberg, Linda, Hultqvist, Greta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477473/
https://www.ncbi.nlm.nih.gov/pubmed/34579778
http://dx.doi.org/10.1186/s40035-021-00258-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477473/
https://www.ncbi.nlm.nih.gov/pubmed/34579778
http://dx.doi.org/10.1186/s40035-021-00258-x

Ejemplares similares